Haptoglobin Phenotype and Breast Cancer Survival
Author Information
Author(s): Gast Marie-Christine W, van Tinteren Harm, Bontenbal Marijke, van Hoesel René QGCM, Nooij Marianne A, Rodenhuis Sjoerd, Span Paul N, Tjan-Heijnen Vivianne CG, de Vries Elisabeth GE, Harris Nathan, Twisk Jos WR, Schellens Jan HM, Beijnen Jos H
Primary Institution: Netherlands Cancer Institute
Hypothesis
Can haptoglobin phenotype predict recurrence-free survival in high-risk primary breast cancer patients?
Conclusion
The haptoglobin phenotype was not found to be a predictor of recurrence-free survival in high-risk primary breast cancer patients after validation.
Supporting Evidence
- Initial results suggested a link between haptoglobin phenotype and recurrence-free survival.
- Validation in a larger sample set showed no significant predictive value for haptoglobin phenotype.
- The study highlights the importance of validating biomarkers in clinical research.
Takeaway
Researchers wanted to see if a specific protein type could help predict if breast cancer patients would stay cancer-free after treatment, but it turned out not to be helpful.
Methodology
The study analyzed serum samples from two sets of high-risk primary breast cancer patients using SELDI-TOF MS and validated findings with one-dimensional gel-electrophoresis.
Potential Biases
The study design and sample collection methods were robust, minimizing bias risks.
Limitations
The initial findings were not confirmed in a larger validation set, indicating potential type I error.
Participant Demographics
Participants were high-risk primary breast cancer patients, with a mean age of 45.8 years in sample set I and 43.9 years in sample set II.
Statistical Information
P-Value
0.5221
Confidence Interval
95% CI: 0.56 – 1.34
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website